These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37183644)

  • 1. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].
    Ren C; Cao H; Zheng J; Sun W; Zhou J
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):291-302. PubMed ID: 37183644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in the treatment of non-small cell lung cancer.
    Mar N; Vredenburgh JJ; Wasser JS
    Lung Cancer; 2015 Mar; 87(3):220-5. PubMed ID: 25601485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of HER2 in NSCLC].
    Zhang K; Wang H
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):644-51. PubMed ID: 26483338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The force of HER2 - A druggable target in NSCLC?
    Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
    Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
    Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
    [No Abstract]   [Full Text] [Related]  

  • 8. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.
    Mar N; Vredenburgh JJ
    Conn Med; 2015 Oct; 79(9):531-5. PubMed ID: 26630704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
    Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
    Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Cappuzzo F
    Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 and lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress of Targeted Therapy for HER2 Gene 
in Advanced Non-small Cell Lung Cancer].
    Kong L; Zhong D
    Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1108-1112. PubMed ID: 33357319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.